Theranexus SAS (ALTHX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Theranexus SAS (ALTHX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8290
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Theranexus SAS (Theranexus) is a biotechnology company that discovers and develops drug combinations for safe and efficient neurological and psychiatric treatments. The company develops THN102, a pipeline product that comprises modafinil. It also offers THN02 for the treatment of sleepiness in narcoleptic patients is in phase 1 of clinical trials. Theranexus uses technology on pharmaceutical modulation of proven and existing central nervous system drugs to make them more safe, enabling the new intellectual property and more adaptable to various classes of CNS drugs. The company formed partners with biomedical research institutes for developing drugs for brain disorders. Theranexus is headquartered in Paris, France.

Theranexus SAS (ALTHX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Theranexus SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Theranexus SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Theranexus SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Theranexus SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Theranexus SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Theranexus SAS, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Theranexus Raises USD4.5 Million in Seed Financing 10
Partnerships 12
Theranexus Enters into Research Agreement with College de France 12
Licensing Agreements 13
Theranexus Enters into Licensing Agreement with CEA and Bio-Modeling Systems 13
Equity Offering 14
Theranexus Raises USD19.6 Million in IPO 14
Theranexus SAS – Key Competitors 15
Theranexus SAS – Key Employees 16
Theranexus SAS – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Financial Announcements 18
Sep 27, 2018: Theranexus announces its first half 2018 results 18
Corporate Communications 19
Oct 11, 2018: Theranexus announces that Rodolphe Besserve will join its Board of Directors 19
Clinical Trials 20
Oct 15, 2018: Theranexus plans to expand its phase II pipeline with a third program 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
Theranexus SAS, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Theranexus SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Theranexus SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Theranexus SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Theranexus SAS, Deals By Therapy Area, 2012 to YTD 2018 8
Theranexus SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Theranexus Raises USD4.5 Million in Seed Financing 10
Theranexus Enters into Research Agreement with College de France 12
Theranexus Enters into Licensing Agreement with CEA and Bio-Modeling Systems 13
Theranexus Raises USD19.6 Million in IPO 14
Theranexus SAS, Key Competitors 15
Theranexus SAS, Key Employees 16

List of Figures
Theranexus SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Theranexus SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Theranexus SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Theranexus SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Theranexus SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Theranexus SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Theranexus SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Theranexus SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Theranexus SAS (ALTHX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Campanile UK Ltd:企業の戦略・SWOT・財務分析
    Campanile UK Ltd - Strategy, SWOT and Corporate Finance Report Summary Campanile UK Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Amil Assistencia Medica Internacional S/A:企業の戦略・SWOT・財務情報
    Amil Assistencia Medica Internacional S/A - Strategy, SWOT and Corporate Finance Report Summary Amil Assistencia Medica Internacional S/A - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Celularity Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Celularity Inc (Celularity) is a biotechnology company that develops and commercializes therapeutics derived from the placenta for autoimmune and degenerative diseases, immuno-oncology, and functional regeneration. The company’s pre-clinical and clinical assets include CAR-T cell receptor an …
  • CynergisTek, Inc. (CTEK):企業の戦略的SWOT分析
    CynergisTek, Inc. (CTEK) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • First Mutual Holdings Limited:企業の戦略・SWOT・財務情報
    First Mutual Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary First Mutual Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Alarko Contracting Group
    Alarko Contracting Group - Strategy, SWOT and Corporate Finance Report Summary Alarko Contracting Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • WPG Holdings Limited:企業の戦略・SWOT・財務情報
    WPG Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary WPG Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Orbit International Corp.:戦略・SWOT・企業財務分析
    Orbit International Corp. - Strategy, SWOT and Corporate Finance Report Summary Orbit International Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Greenhill & Co Inc:企業の戦略・SWOT・財務情報
    Greenhill & Co Inc - Strategy, SWOT and Corporate Finance Report Summary Greenhill & Co Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Recylex SA:企業の戦略・SWOT・財務情報
    Recylex SA - Strategy, SWOT and Corporate Finance Report Summary Recylex SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Oracle Financial Services Software Limited (OFSS):企業の財務・戦略的SWOT分析
    Oracle Financial Services Software Limited (OFSS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • Seneca Biopharma Inc (CUR):企業の財務・戦略的SWOT分析
    Summary Seneca Biopharma Inc(Seneca) formerly known as Neuralstem Inc, is a biopharmaceutical company that develops novel treatments for nervous system diseases. The company offers cell therapy treatment for ALS, ischemic stroke, spinal cord injury, multiple sclerosis, optic neuritis, Alzheimer’s di …
  • Itausa – Investimentos Itau SA (ITSA4):企業の財務・戦略的SWOT分析
    Itausa - Investimentos Itau SA (ITSA4) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Cellerant Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Cellerant Therapeutics Inc (Cellerant) develops novel immunotherapies for oncology and blood-related disorders. Its lead product, CLT-008, is a myeloid progenitor cell therapy which is in Phase 2 clinical development in patients with acute myeloid leukemia (AML). Cellerant develops various c …
  • Ocular Therapeutix Inc (OCUL):企業の財務・戦略的SWOT分析
    Summary Ocular Therapeutix Inc (Ocular), formerly I-Therapeutix Inc is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for diseases using hydrogel platform technology. The company’s products include DEXTENZA, sustained release travoprost and posterior …
  • BICE Vida Compania de Seguros S.A.:企業の戦略・SWOT・財務情報
    BICE Vida Compania de Seguros S.A. - Strategy, SWOT and Corporate Finance Report Summary BICE Vida Compania de Seguros S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Caprion Biosciences Inc:医療機器:M&Aディール及び事業提携情報
    Summary Caprion Biosciences Inc (Caprion) is a provider of proteomics and immune monitoring services. The company provides proteomic based services such as neo-epitope discovery and characterization, biomarker discovery, fit-for-purpose assays, host cell protein detection, PK assays, and others. It …
  • Alliancebernstein Holding Lp
    Alliancebernstein Holding Lp - Strategy, SWOT and Corporate Finance Report Summary Alliancebernstein Holding Lp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Cintas Corporation:企業の戦略・SWOT・財務情報
    Cintas Corporation - Strategy, SWOT and Corporate Finance Report Summary Cintas Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Mologic Ltd-医療機器分野:企業M&A・提携分析
    Summary Mologic Ltd (Mologic) is a medical device company that designs, develops, manufactures and markets in vitro diagnostic medical devices. The company’s products include bacterial vaginosis test kit, peritoneal dialysis test, lateral flow kit, desmosine ELISA kit and FMLP ELISA kit. Its experti …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆